Abstract
Adequate very sensitive quantification methods are needed for the development and are also now required for the monitoring of undesirable solid form(s) as routine tests. The pre-requisite for quantitation are selectivity, sensitivity and most important the purity of standards and their proper storage, what is a challenge for metastable forms.
Several analytical techniques are available such as X-ray diffraction, spectroscopy, thermal analysis and microcalorimetry. The different steps of the validation of the analytical methods and problems to be solved are discussed. Examples illustrate the different techniques and compare their possible advantages and limits. The relative standard deviation of measurements should allow for checking the homogenization procedure of mixtures for calibration. The validation should be carried out following ICH guidelines for validation of analytical methods. Comparison of different techniques in adequate concentration range add confidence in the analytical results.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.References
J. K. Haleblian and W. J. McCrone, Pharm. Sci., 58 (1969) 911.
J. K. Haleblian, Pharm. Sci., 64 (1975) 1269.
International Conference on Harmonization (ICH), Guideline Specification Q6A, Decision Tree: Investigating the need to set acceptance criteria for polymorphism in drug substances and drug products, 1999.
Abbreviated New Drug Application (ANDA) Process for Generic Drugs, FDA. gov.
W. H. DeCamp, Amer. Pharm. Rev., 4 (2001) 70.
L. X. Yu, M. S. Furnes, A. Raw, K. P. Woodland Outlaw, N. E. Nashed, E. Ramos, S. P. F. Miler, R. C. Adams, F. Fang, R. M. Patel, F. O. Holcombe, Y. Chiu and A. S. Hussain, Pharm. Res., 20 (2003) 531.
S. A. Raw, M. S. Furness, D. S. Gill, R. C. Adams, F. O. Holcombe and L. Yu, Adv. Drug Del. Rev., 56 (2004) 397.
D. Giron, Eng. Life Sci., 3 (2003) 103.
D. Giron, S. Garnier and M. Mutz, J. Therm. Anal. Cal., 77 (2004) 709.
A. Burger and R. Ramberger, Mikrochim. Acta, II (1979) 259.
D. Giron, Labo-Pharma-Probl. Techn., 307 (1981) 151.
Polymorphism in Pharmaceutical Solids, H. G. Brittain Ed., Marcel Dekker, New York, 1999.
Polymorphism in Molecular Crystals, J. Bernstein, Oxford University Press, Oxford, 2002.
M. R. Caira, Design of Organic Solids in Topics in current Chemistry, 98 (1998) 163.
R. Hilfiker, Polymorphism: in the Pharmaceutical Industry, 2006, Wiley-VCH, Weinheim.
L. Borka and J. K. Haleblian, Acta Pharm. Jugosl., 40 (1990) 71.
D. Giron, Thermochim. Acta, 248 (1995) 1.
M. Kühnert-Branstätter, Thermomicroscopy in the Analysis of Pharmaceuticals, Pergamon, NY., 1971.
M. Pudipeddi and A. T. M. Serajuddin, J. Pharm. Sci., 94 (2005) 929.
S. R. Byrn, R. R. Pfeiffer and J. G. Stowell, Solid-State Chemistry of drugs, 2nd Ed., SSCI Inc., West Lafayette, Indiana, 1999.
International harmonisation guideline Q2 on validation of analytical procedures, 1996. US29, first supplement, 3614–3617.
G. A. Stephenson, The Rigaku Journal, 92 (2005) 2.
S. S. Iyengar, N. V. Phadnis and R. Suryanarayanan, Powder Diffraction, 16 (2001) 20.
R. Surana and R. Suryanarayanan, Powder Diffraction, 15 (2000) 2.
M. Davidovich, J. Z. Gougoutas, R. P. Scaring, I. Vittez and S. Yin, Am. Pharm. Rev., 7 (2004).
S. Yin, R. P. Scaring, J. DiMarco, M. Gaella and J. Z. Gougoutas, Am. Pharm. Rev., 6 (2003) 80.
S. D. Clas, R. Faizer, R. E. O’Connor and E. B. Vadas, Int. J. Pharm., 121 (1995) 73.
D. Giron, B. Edel and P. Piechon, Mol. Cryst. Liq. Cryst., 187 (1990) 297.
V. B. Cooper, G. E. S. Pearce and E. R. Petts, J. Pharm. Pharmacol., 55 (2003) 1323.
X-ray diffraction, USP 29.
D. Giron, J. Therm. Anal. Cal., 64 (2001) 37.
D. Giron, J. Therm. Anal. Cal., 73 (2003) 441.
ASTME1655-00. ’Standard Practice for IR quantitative Analysis’, ASTM International, West Conshohocken, PA.
D. E. Bugay, Adv. Drug Deliv. Rev., 48 (2001) 43.
R. Helmy, G. X. Zhou, Y. W. Chen, L. Crocker, T. Wang, R. M. Wenslow and A. Vailaya, Anal. Chem., 75 (2003) 605.
S. Agatonovic-Kustrin, T. Rades, V. Wu, D. Saville and I. G. Tucker, J. Pharm. Biomed. Anal., 25 (2001) 741.
M. Sheikhzadeh, S. Rohan, A. Jutan, T. Manifar, K. Murthy and S. Horne, Pharm. Res., 23 (2006) 1043.
V. Koradia, G. Chawwla and A. K. Bansai, Acta Pharmaceutica, 54 (2004) 193.
Eur. Ph., 2005, 5, section 2.2.24.
EMEA, Guideline for the development and Validation of NIR Methods in the Pharmaceutical Industry, N. Broad, P. Graham, P. Hailey, A. Hardy, S. Holland, S. Hughes, D. Lee, K. Prebble and N. Salton.
NIR 〈119〉, USP 2006, 29, 2979–2983.
A. D. Patel, P. E. Luner and M. S. Kemper, J. Pharm. Sci., 90 (2001) 360.
M. Otsuka, F. Kato and Y. Matsuda, Analyst, 126 (2001) 1578.
Raman 〈1120〉, USP 29 (2006) 2983. Eur. Ph., 2005, 5, section 2.02.
R. S. Campbell, N. Sarra, A. C. Williams, I. M. Grimsey and S. W. Booth, J. Pharm. Biomed. Anal., 28 (2002) 1135.
L. S. Taylor, Am. Pharm. Rev., 4 (2001) 60.
C. J. Strachan, P. F. Taday, D. A. Newnham, K. C. Gordon, J. A. Zeitler, M. Pepper and T. Rades, J. Pharm. Sci., 94 (2005) 837.
Y. Hu, H. Wikstrom, S. Byrn and L. S. Taylor, Appl. Spectroscopy, 60 (2006) 977.
P. A. Tishmack, D. E. Bugay and S. R. Byrn, J. Pharm. Sci., 92 (2003) 441.
M. T. Zell, B. E. Padden, D. J. W. Grant, S. A. Schroeder, K. L. Wachholder, I. Prakash and E. J. Munson, Tetrahedron, 56 (2000) 6603.
D. C. Apperley, R. K. Harris, T. Larsson and T. Malmstrom, J. Pharm. Sci., 92 (2003) 2487.
R. K. Harris, Analyst, 131 (2006) 351.
USP29, 2006, 2666–2667.
R. Saklatvala, P. G. Royal and D. Q. M. Craig, Int. J. Pharm., 192 (1999) 55.
M. Lappalainen, I. Pitkaenen and P. Harjunen, Int. J. Pharm., 307 (2006) 150.
G. M. Venkatesh, M. E. Barnett, C. Owusu-Fordjour and M. Galop, Pharm. Res., 18 (2001) 98.
USP Solution calorimetry.
P. Royall and S. Gaisford, Curr. Pharm. Biotechnol., 6 (2005) 215
M. Anberg, C. Nyström and S. Castensson, Int. J. Pharm., 81 (1992) 153.
D. Giron, P. Remy, S. Thomas and E. Vilette, J. Thermal Anal., 48 (1997) 465.
M. Anberg, Thermochim. Acta, 248 (1995) 161.
K. Fiebich and M. Mutz, J. Therm. Anal. Cal., 57 (1999) 75.
H. Ahmed, G. Buckton and D. A. Rawlins, Int. J. Pharm., 130 (1996) 195.
K. Kawakami, T. Numa and Y. Ida, J. Pharm. Sci., 91 (2002) 417.
S. Garnier, D. Giron and M. Mutz, ’Study of crystallization of drug substances under solvent vapour atmosphere by microcalorimetry’, PhandTA7, Innsbruck, Sept. 2003.
G. Buckton, Thermochim. Acta, 247 (1994) 117. G. Buckton and P. L. Sheridan, Pharm. Res., 12 (1995) 1025.
S. E. Hogan and G. Buckton, Int. J. Pharm., 227 (2001) 57.
S. E. Dilworth, G. Buckton, S. Gaisford and R. Ramos, Int. J. Pharm., 284 (2004) 83.
V. Lehto, M. Tenho, K. Vaehae-Heikkilae, P. Harjunen, M. Paeaellysaho, J. Vaelisaari, P. Niemelae and K. Jaervinen, Powder Technology, 167 (2006) 85.
C. Guftasson, H. Lennholm, T. Iversen and C. Nystrom, Int. J. Pharm., 174 (1998) 243.
I. Fix and K.-J. Steffens, Drug Dev. Ind. Pharm., 30 (2004) 513.
D. Pratiwi, J. P. Fawcett, K. C. Gordon and T. Rades, Eur. J. Pharm., 54 (2002) 337.
P. Royall, C. Huang, S. Jai Tang, J. Duncan, G. Vandevelde and M. Brown, Int. J. Pharm., 301 (2005) 181.
T. M. Niemczyk, 2003 ’Quantitative analysis of polymorphic mixtures using infrared spectroscopy’. University of New Mexico.
T. Okumura and M. Otsuka, J. Pharm.Sci., 94 (2005) 1013.
D. Giron, Mol. Cryst. Liq. Cryst., 161 (1987) 77.
D. Giron, P. Piechon, C. Goldbronn and S. Pfeffer, J. Therm. Anal. Cal., 57 (1999) 61.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Giron, D., Monnier, S., Mutz, M. et al. Comparison of quantitative methods for analysis of polyphasic pharmaceuticals. J Therm Anal Calorim 89, 729–743 (2007). https://doi.org/10.1007/s10973-006-7962-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10973-006-7962-y